Welcome to our April research update! Getting involved with research is an important way to impact asthma and allergy treatments, education, and awareness. This month, we are highlighting clinical trials, surveys, and news on: Adults with asthma Approval of a treatment for kids with severe asthma Asthma and allergy control and quality of life Gaps in care for people with severe uncontrolled asthma Note: The links below will take you to external websites. Asthma and Allergy Clinical Trials ..read more

Teva Pharmaceutical Industries Ltd. plans to discontinue all its Digihaler® products sold in the U.S. on June 1. This includes: ProAir Digihaler , AirDuo Digihaler , and ArmonAir Digihaler . Both ProAir and AirDuo are available in Teva’s Respiclick products – the same medicine formulations without the digital component. Teva does not offer the ArmonAir formulation in a branded alternative or generic. The ArmonAir Digihaler is an inhaler that had been recommended as another option for ..read more

Updated as of April 3, 2024: We did it! We took awareness of asthma inhaler pricing all the way to the White House! The Asthma and Allergy Foundation of America (AAFA) joined President Biden and Senator Bernie Sanders today for a briefing on health care costs and inhaler pricing. The White House invited AAFA President and CEO Kenneth Mendez and AAFA Senior Director of Policy and Advocacy Jenna Riemenschneider in recognition of our advocacy work to advance health equity for people with ..read more

Welcome to our March research update! Getting involved with research is an important way to impact asthma and allergy treatments, education, and awareness. This month, we are highlighting clinical trials, surveys, and news on: Adults with asthma Epinephrine nasal spray Dupilumab for moderate-to-severe asthma and chronic obstructive pulmonary disease (COPD) COVID-19 vaccination during pregnancy Treatment for chronic spontaneous urticaria (CSU) Asthma and Allergy Clinical Trials Are You ..read more

The Asthma and Allergy Foundation of America (AAFA) continues to push for efforts to lower the cost of asthma medicines, such as inhalers. We know the high cost of medicine can be a barrier to treatment. AAFA welcomes the news that AstraZeneca is lowering the out-of-pocket cost of its inhaled respiratory products to $35 a month. The covered products include: AIRSUPRA® (albuterol and budesonide) inhalation aerosol BEVESPI AEROSPHERE® (glycopyrrolate and formoterol fumarate) inhalation aerosol ..read more

The essay below was written by Kenneth Mendez, President and CEO of the Asthma and Allergy Foundation of America (AAFA), for the op-ed section of the Boston Globe on March 11, 2024. A major drug manufacturer recently replaced its popular, branded inhaler, Flovent, with a cheaper generic version . The generic is exactly the same as the more expensive Flovent. Great news for people with asthma? Think again. Following the launch of the low-cost generic alternative, thousands of people with ..read more

The Asthma and Allergy Foundation of America (AAFA) released our 2024 Allergy Capitals™ report . AAFA’s report ranks the top 100 most challenging cities in the contiguous United States (“lower 48 states”) to live with seasonal pollen allergies. The report includes data from the previous year to create a ranking of the 100 most populated cities based on: Tree, grass, and weed pollen scores Over-the-counter allergy medicine use Availability of board-certified allergists/immunologists Wichita ..read more

The Asthma and Allergy Foundation of America (AAFA) recently called for national action to address the high costs of asthma medicine. Following that call, drug manufacturer Boehringer Ingelheim announced it is capping the price of its inhalers at $35 a month for people with private insurance. The covered products include: Atrovent ® HFA (ipratropium bromide HFA) inhalation aerosol Combivent ® Respimat ® (ipratropium bromide and albuterol) inhalation spray Spiriva ® HandiHaler ® (tiotropium ..read more

On Feb. 8, 2024, members of the Asthma and Allergy Foundation of America’s (AAFA) Board of Directors came to Washington, D.C., to advocate for the asthma and allergy community. They met with their senators and representatives to teach them about some of AAFA’s priorities to reduce the burden of disease for the more than 100 million people in the United States with asthma and/or allergies. Over the course of the day, AAFA board members met with 28 offices to share information about funding ..read more

Do you know about the allergic march? This is the name for the natural history of allergic diseases. This refers to how allergic diseases progress in a person over time. It usually starts in infants as dry skin. It can then progress during childhood to eczema (atopic dermatitis), food allergy, nasal allergies, and asthma. John James, MD, board-certified allergist, and the Asthma and Allergy Foundation of America (AAFA) will explore the allergic march in our upcoming webinar. During the ..read more